About clearmind medicine inc - CMND
Clearmind Medicine, Inc. is a psychedelic pharmaceutical biotech company. It focuses on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize it as regulated medicines, foods, or supplements. The company was founded on July 18, 2017 and is headquartered in Vancouver, Canada.
CMND At a Glance
Clearmind Medicine, Inc.
1220 West 6th Avenue
Vancouver, British Columbia V6H 1A5
| Phone | 1-973-536-1016 | Revenue | 0.00 | |
| Industry | Other Metals/Minerals | Net Income | -5,254,678.00 | |
| Sector | Non-Energy Minerals | Employees | N/A | |
| Fiscal Year-end | 10 / 2025 | |||
| View SEC Filings |
CMND Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.908 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.439 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.021 |
CMND Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
CMND Liquidity
| Current Ratio | 1.716 |
| Quick Ratio | 1.716 |
| Cash Ratio | 1.661 |
CMND Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -79.564 |
| Return on Equity | -256.888 |
| Return on Total Capital | -166.251 |
| Return on Invested Capital | -255.861 |
CMND Capital Structure
| Total Debt to Total Equity | 1.71 |
| Total Debt to Total Capital | 1.681 |
| Total Debt to Total Assets | 0.732 |
| Long-Term Debt to Equity | 0.528 |
| Long-Term Debt to Total Capital | 0.519 |